G1 Therapeutics Presents Updated Data at ESMO 2019 from Randomized Phase 2 Trial of Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement in Overall Survival

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice